Loxoprofen
Non-steroidal anti-inflammatory drug
- M02AA31 (WHO)
- JP: Class 1 OTC
BR: Red Stripe (Rx only)
- (RS)-2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid
- 68767-14-6
N
- 3965
- DB09212
Y
- 3828 Y
- 3583H0GZAP
- D08149 Y
- CHEBI:76172 N
- ChEMBL19299 Y
- DTXSID1045164
- Interactive image
- O=C2C(Cc1ccc(cc1)C(C(=O)O)C)CCC2
- InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)Y
- Key:YMBXTVYHTMGZDW-UHFFFAOYSA-NY
N
Y (what is this?) (verify)Loxoprofen is a nonsteroidal anti-inflammatory drug (NSAID) in the propionic acid derivatives group, which also includes ibuprofen and naproxen among others. It is available in some countries for oral administration. A transdermal preparation was approved for sale in Japan in January 2006;[1] medicated tape and gel formulations followed in 2008 and 2010.
It was patented in 1977 and approved for medical use in 1986.[2]
Pharmacokinetics
Loxoprofen is a prodrug. It is quickly converted to its active trans-alcohol metabolite following oral administration, and reaches its peak plasma concentration within 30 to 50 minutes.
Mechanism of action
As most NSAIDs, loxoprofen is a non-selective cyclooxygenase inhibitor, and works by reducing the synthesis of prostaglandins from arachidonic acid.
Interactions
Loxoprofen should not be administered at the same time as second-generation quinolone antibiotics such as ciprofloxacin and norfloxacin, as it increases their inhibition of GABA and this may cause seizures.[3] It may also increase the plasma concentration of warfarin, methotrexate, sulfonylurea derivatives and lithium salts, so care should be taken when loxoprofen is administered to patients taking any of these drugs.[3]
Brand names
It is marketed in Brazil, Mexico, China and Japan by Sankyo as its sodium salt, loxoprofen sodium, under the trade name Loxonin; in Argentina as Oxeno; in India as Loxomac; in Thailand as Japrolox; and in Saudi Arabia as Roxonin and Roxonin Tape.
A generic drug is marketed in Brazil by Aché as Oxotron. In Japan, two fixed dose combinations are available: Loxonin S Plus, with magnesium oxide, and Loxonin S Premium, with apronal, caffeine, and aluminium magnesium silicate.
References
- ^ Daiichi Sankyo Co. (January 24, 2006). "Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin Poultice 100mg Receives Approval for Manufacture" (Press release). Doctor's Guide Global Edition. Retrieved 2007-04-19.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 521. ISBN 9783527607495.
- ^ a b "LOXONIN - Bula do Medicamento [Label Information]" (in Portuguese). Centralx. 2007. Retrieved 2007-04-19.
Wikimedia Commons has media related to Loxoprofen.
- v
- t
- e
pyrazolidines
and related substances
- Ampiroxicam
- Droxicam
- Isoxicam
- Lornoxicam
- Meloxicam
- Piroxicam
- Pivoxicam
- Tenoxicam
derivatives (profens)
- Alminoprofen
- Benoxaprofen†
- Carprofen‡
- Dexibuprofen
- Dexketoprofen
- Fenbufen
- Fenoprofen
- Flunoxaprofen
- Flurbiprofen
- Ibuprofen#
- Ibuproxam
- Indoprofen†
- Ketoprofen
- Loxoprofen
- Miroprofen
- Naproxen
- Oxaprozin
- Pelubiprofen
- Piketoprofen
- Pirprofen
- Suprofen
- Tarenflurbil
- Tepoxalin‡
- Tiaprofenic acid
- Vedaprofen‡
- Zaltoprofen
- COX-inhibiting nitric oxide donator: Naproxcinod
acids (fenamates)
(coxibs)
combinations
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use.
category
commons
portal
